Lataa...
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Activating mutations in RAS family proteins are found in ~25% of all human cancers. Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten RAS (KRAS) being the most frequently mutated isoform. Historically, KRAS has been acknowledged as “undruggable”, largely b...
Tallennettuna:
| Julkaisussa: | Pharmaceutics |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8147792/ https://ncbi.nlm.nih.gov/pubmed/34064352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13050653 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|